praveen
06-12-2007, 08:35 PM
Ranbaxy Laboratories Ltd on December 6 announced that it has received approval to manufacture and market Coviro-LS kid and Coviro-LS kid DS, both double anti-retroviral (ARV) and fixed dose combination dispersible tablets for children in India.
The company has also filed the products with WHO Geneva for pre-qualification.
The products are indicated for treatment of HIV infection in children
The company has also filed the products with WHO Geneva for pre-qualification.
The products are indicated for treatment of HIV infection in children